Literature DB >> 4907560

L-Dopa and Parkinsonism.

D B Calne, M Sandler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4907560     DOI: 10.1038/226021a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  14 in total

1.  Dentatectomy: absence of effects on dyskinesias arizing from chemical stimulation of the striatum in rats.

Authors:  D L Murphey; R E Dill
Journal:  Experientia       Date:  1972-01-15

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

3.  Treatment of involuntary movement disorders with tetrabenazine.

Authors:  M Swash; A H Roberts; H Zakko; K W Heathfield
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-04       Impact factor: 10.154

4.  A monamine oxidase-tetrazolium reaction for locating aromatic amino acid decarboxylases in electrophoretic media.

Authors:  K N Antonas; W F Coulson; J B Jepson
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

5.  Lisuride, a potent drug in the treatment of muscular rigisity in rats.

Authors:  D Loos; K Halbhübner; H Herken
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

6.  In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.

Authors:  R D Johnson; C R Ruthven; B L Goodwin; M Sandler
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

7.  Amantadine antagonism of oxotremorine effects.

Authors:  Y Eshel; A D Korczyn
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

8.  Pyridoxal 5'-phosphate levels in brain after treatments which impair cerebral glucose metabolism.

Authors:  K L Wong; G M Tyce
Journal:  Neurochem Res       Date:  1979-12       Impact factor: 3.996

9.  1-Hydroxy-3-amino-pyrrolidone-2(HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases.

Authors:  I L Bonta; C J De Vos; H Grijsen; F C Hillen; E L Noach; A W Sim
Journal:  Br J Pharmacol       Date:  1971-11       Impact factor: 8.739

10.  Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors.

Authors:  T A Cawley; T J Shickley; M R Ruggieri; G R Luthin
Journal:  J Pharmacol Exp Ther       Date:  1993-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.